{"id":"NCT02643420","sponsor":"Spectrum Pharmaceuticals, Inc","briefTitle":"SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)","officialTitle":"RAnDomized Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast CANCEr Patients Receiving Docetaxel and Cyclophosphamide (TC) (ADVANCE)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-01-19","primaryCompletion":"2018-01-24","completion":"2018-10-31","firstPosted":"2015-12-31","resultsPosted":"2022-03-02","lastUpdate":"2022-03-02"},"enrollment":406,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Neutropenia","Breast Cancer"],"interventions":[{"type":"DRUG","name":"SPI-2012","otherNames":["Rolontis®","Eflapegrastim","(HM10460A)"]},{"type":"DRUG","name":"Pegfilgrastim","otherNames":["Neulasta®"]},{"type":"DRUG","name":"Docetaxel","otherNames":["Taxotere"]},{"type":"DRUG","name":"Cyclophosphamide","otherNames":["Cytoxan"]}],"arms":[{"label":"Arm 1: SPI-2012 and Docetaxel + Cyclophosphamide (TC)","type":"EXPERIMENTAL"},{"label":"Arm 2: Pegfilgrastim and Docetaxel + Cyclophosphamide (TC)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to compare the efficacy of a single dose of SPI-2012 versus pegfilgrastim in participants with early-stage breast cancer receiving docetaxel and cyclophosphamide (TC), as measured by the duration of severe neutropenia (DSN) in Cycle 1.","primaryOutcome":{"measure":"Duration of Severe Neutropenia (DSN) in Cycle 1","timeFrame":"Day 1 and Days 4-15 in Cycle 1 (each cycle was 21 days)","effectByArm":[{"arm":"Arm 1: SPI-2012 and TC","deltaMin":0.2,"sd":0.503},{"arm":"Arm 2: Pegfilgrastim and TC","deltaMin":0.35,"sd":0.683}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":10},"locations":{"siteCount":81,"countries":["United States","Canada","South Korea"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":36,"n":197},"commonTop":["Fatigue","Nausea","Alopecia","Diarrhoea","Lymphocyte count decreased"]}}